Posts Tagged 'anti-coagulant'

Doctor says blood thinner carries risks

In a column in the Spokesman-Review out of Washington, Dr. Anthony L. Komaroff, M.D., answers a letter-writer’s question about the blood-thinner Pradaxa.

The letter-writer says his wife has atrial fibrillation, and her medication was recently changed from warfarin to Pradaxa. He wants to know if she’s right in claiming that the medicine is just as effective, although it requires fewer tests.

Komaroff writes that technically, Pradaxa is just as effective in preventing blood clots. But Pradaxa presents some risks that warfarin, the ...

continue reading...

Blood thinner approval has competitors ‘on their toes’

A report on the blog FiercePharma says the approval of blood thinner Eliquis in Europe has the manufacturers of competing medications “on their toes.”

Eliquis, from Pfizer and Bristol-Myers Squibb, was developed as an alternative to warfarin, which for decades has been the standard treatment for blood clot prevention.

But according to FiercePharma, warfarin “comes with a host of dosage-tweaking rules, plus interactions with alcohol and food, so it is difficult ...

continue reading...

FDA approves new blood thinner

The U.S. Food and Drug Administration has approved a new blood thinner manufactured by Pfizer Inc. and Bristol-Myers Squibb. A Bloomberg report describes Eliquis as a “potential blockbuster heart drug.”

The Food and Drug Administration cleared Eliquis for the prevention of blood clots that develop in patients with the heart rhythm disorder atrial fibrillation, after the manufacturers failed in two previous efforts to win approval for the drug.

It’s among a ...

continue reading...

Blood thinner approved in Japan

Regulators in Japan have approved the blood thinner Eliquis, the Japan Daily Times reports.

Eliquis is the brand name for apixaban, manufactured by Bristol-Myers Squibb Co and Pfizer Inc. It’s among a new class of blood thinners meant to replace decades-old warfarin, which is effective but can be difficult to use because it requires dietary restrictions and frequent testing.

Pharmaceutical companies have been looking to warfarin alternatives as potentially profitable areas ...

continue reading...

Plaintiffs: Dangerous blood thinner not a true alternative

The blood thinner Pradaxa has generated about $1.48 billion in worldwide sales over a span of less than two years. According to a story in Bloomberg, that’s largely because manufacturer Boehringer Ingelheim has been marketing it as a more convenient alternative to an existing medication.

Unlike the blood thinner warfarin, which has been around since the 1950s, Pradaxa does not require frequent blood testing and dietary restrictions.

But plaintiffs in numerous ...

continue reading...

Blood thinner shows promise in study

A new study is reporting good results for extended use of the blood thinner apixaban produced by Pfizer Inc. and Bristol-Myers Squibb Co.

A Reuters story says researchers found the drug, sold under brand name Eliquis, reduced the risk of recurrence of potentially deadly clots in the veins and lungs by 80 percent, with no increase in major bleeding.

Apixaban is among a new class of blood thinners meant to replace ...

continue reading...
Page 1 of 3 123